Alkermes plc

Item 1.02. Termination of a Material Definitive Agreement. On July 6, 2026, Alkermes plc (the “Company”) and Amneal Pharmaceuticals LLC (“Amneal”) terminated the previously disclosed Authorized Generic Product Supply Agreement entered into on September 9, 2025 (the “Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Agreement. Under the Agreement, Alkermes Pharma Ireland Limited (“APIL”), a wholly-owned indirect subsidiary of the Company, granted Amneal certain rights to distribute and sell in the United States a limited quantity of an authorized generic version of VIVITROL® (naltrexone for extended-release injectable suspension) for a one-year term beginning on the date of a Third Party ANDA Product Launch (such authorized generic product, the “Amneal AG Product”) in exchange for payment for the supply of the Amneal AG Product at a premium to APIL’s fully burdened manufacturing cost and a share of any Net Profits realized from the sales of the Amneal AG Product. The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement, a copy of which was filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. After the Company notified Amneal that it had not met certain terms of the Agreement, which Amneal had a period of time to remedy, Amneal notified the Company, prior to the expiry of such period, that it did not wish to order any Batches under the Agreement. The Company did not incur any penalties in connection with the termination of the Agreement and, after the termination, no further payments or obligations are owed by APIL or Amneal under the Agreement. Further, in connection with this termination, the parties agreed to release any and all claims against one another and their respective affiliates, successors, assigns and other representatives arising out of or related to the Agreement.